Syndax Q1 net loss $72.4M ($0.85/shr); revumenib NDA & axatilimab BLA under Priority Review

Syndax Pharmaceuticals Inc

2024-Q1 EPS reported -$0.85

Cash, equivalents and investments $522M; management believes sufficient for operations through 2026.
Revumenib NDA for R/R KMT2Ar acute leukemia granted Priority Review; PDUFA date Sep 26, 2024.
Axatilimab BLA for chronic GVHD granted Priority Review; PDUFA date Aug 28, 2024.
Enrollment completed in AUGMENT-101 mNPM1 cohort; topline data expected 4Q24, potential sNDA 1H25.
Appointed Steven Closter as Chief Commercial Officer; R&D expenses rose to $56.5M from $34.1M YoY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Syndax Pharmaceuticals Inc reported the quarter ended March 31, 2024 results: net income net loss attributable to common stockholders of $72.4 million, EPS $0.85 per share.

Period: the quarter ended March 31, 2024
Net income: net loss attributable to common stockholders of $72.4 million
EPS: $0.85 per share
Result: reported results

Exact text from the filing

Syndax reported a net loss attributable to common stockholders of $72.4 million, or $0.85 per share, compared to a net loss attributable to common stockholders of $41.1 million, or $0.59 per share, for the comparable prior year period

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0000950170-24-055052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.